Teladoc: Mixed Results, Structural Headwinds, and Below-Consensus Outlook Justify Neutral Stance

William Blair analyst Ryan Daniels has maintained their neutral stance on TDOC stock, giving a Hold rating on February 18.

Ryan Daniels has given his Hold rating due to a combination of factors tied to Teladoc’s mixed operating profile and outlook. The company delivered quarterly revenue and adjusted EBITDA mildly ahead of consensus, and integrated care showed modest growth with solid profitability, but these positives were offset by ongoing softness at BetterHelp, where revenue declined and margins compressed amid weaker marketing efficiency and conversion.

At the same time, management’s full‑year 2026 guidance came in below market expectations, reinforcing the view that Teladoc is still working through a multi‑year transition. Daniels highlights structural headwinds including the pivot from subscription to visit-based fees, elongated and uncertain enterprise buying cycles, and the operational and execution risk around moving BetterHelp toward broader in‑network coverage, leading him to see limited near‑term upside and thus maintain a neutral stance on the shares.

According to TipRanks, Daniels is an analyst with an average return of -1.2% and a 40.72% success rate. Daniels covers the Healthcare sector, focusing on stocks such as TransMedics Group, Healthcare Services, and Phreesia.

In another report released on February 18, BTIG also maintained a Hold rating on the stock with a $0.00 price target.